<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881409</url>
  </required_header>
  <id_info>
    <org_study_id>ELVIS</org_study_id>
    <nct_id>NCT04881409</nct_id>
  </id_info>
  <brief_title>Nasal High-flow Compared to Non-invasive Ventilation in Treatment of Acute Acidotic Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Nasal High-flow Compared to Non-invasive Ventilation in Treatment of Acute Acidotic Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease - a Randomized Controlled Noninferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ELVIS study compares the nasal high-flow to non-invasive ventilation in treatment of&#xD;
      acute acidotic hypercapnic exacerbation of chronic obstructive pulmonary disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ELVIS study is a prospective, randomized, multi-centre open label trial following a&#xD;
      non-inferiority design to compare the nasal high-flow (NHF) to non-invasive ventilation (NIV)&#xD;
      in treatment of acute acidotic hypercapnic exacerbation of chronic obstructive pulmonary&#xD;
      disease. Accoring to the randomization the patient is treated with NHF or NIV until&#xD;
      discharge. A change of device is possible, if switch criteria are fulfiled OR need for&#xD;
      intubation criteria are met before 72h (timepoint for primary endpoint).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">October 6, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 6, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomization to NHF or NIV</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion with treatment failure of allocated respiratory support within 72 h after start of respiratory support.</measure>
    <time_frame>start of treatment until 72 hours</time_frame>
    <description>Treatment failure defined as&#xD;
intubation or&#xD;
switch to another method of non-invasive ventilation or&#xD;
death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intubation within 72 hours (component of primary outcome)</measure>
    <time_frame>start of treatment until 72 hours</time_frame>
    <description>independent of whether or not responsible primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion intubated within 7 calendar days after hospitalisation/randomization</measure>
    <time_frame>start of treatment until 7 calender days after hospitalisation/randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at day 28 and day 90</measure>
    <time_frame>start of treatment until day 90 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Invasive) ventilator-free days until day 28</measure>
    <time_frame>start of treatment until day 28 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Invasive) ventilator-free hours until the primary endpoint is reached or 72 hours, whichever comes first</measure>
    <time_frame>start of treatment until maximum 72 hours after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) and hospital lengths of stay</measure>
    <time_frame>start of treatment until discharge or day 90 after start of treatment (whichever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion requiring sedation</measure>
    <time_frame>start of treatment until discharge or day 90 after start of treatment (whichever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>switch to another method of non-invasive ventilation within 72 hours (component of primary outcome)</measure>
    <time_frame>start of treatment until 72 hours</time_frame>
    <description>independent of whether or not responsible primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death within 72 hours (component of primary outcome)</measure>
    <time_frame>start of treatment until 72 hours</time_frame>
    <description>independent of whether or not responsible primary endpoint</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>COPD Exacerbation Acute</condition>
  <arm_group>
    <arm_group_label>nasal high-flow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with AECOPD is treated with NHF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-invasive ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient with AECOPD is treated with NIV</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respiratory support with nasal high-flow (NHF)</intervention_name>
    <description>Patient with AECOPD is treated with NHF.</description>
    <arm_group_label>nasal high-flow</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respiratory support with non-invasive ventilation (NIV)</intervention_name>
    <description>Patient with AECOPD is treated with NIV.</description>
    <arm_group_label>non-invasive ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. acute hypercapnic exacerbation of chronic obstructive pulmonary disease with pH &lt; 7.35&#xD;
&#xD;
          2. pCO2 &gt; 45mmHg&#xD;
&#xD;
          3. age ≥ 18 years&#xD;
&#xD;
          4. written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. immediate need for intubation (acc. to intubation criteria in this protocol)&#xD;
&#xD;
          2. pH &lt; 7.15&#xD;
&#xD;
          3. BMI ≥ 35 kg/m²&#xD;
&#xD;
          4. established home-NIV or home-CPAP&#xD;
&#xD;
          5. end-stage disease with DNI/DNR order&#xD;
&#xD;
          6. diseases that could influence the primary endpoint: e.g. acute heart infarction,&#xD;
             cardiogenic lung edema, acute and massive lung embolism (hypertensive), chronic&#xD;
             dialysis with metabolic acidosis, unstable rib fracture influencing ventilation,&#xD;
             injury to the face prohibiting use of a face mask&#xD;
&#xD;
          7. acute disease that precludes participation in the trial&#xD;
&#xD;
          8. tracheotomized patients&#xD;
&#xD;
          9. psychological/mental or other inabilities to supply required informed consent&#xD;
&#xD;
         10. participation in other interventional trials&#xD;
&#xD;
         11. suspected lack of compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hubert Wirtz</last_name>
    <phone>00493419712601</phone>
    <email>hubert.wirtz@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Köppe-Bauernfeind</last_name>
    <phone>00493419716266</phone>
    <email>nicole.koeppe-bauernfeind@zks.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Emden</name>
      <address>
        <city>Emden</city>
        <state>Lower Saxony</state>
        <zip>26721</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Bräunlich, PD Dr.</last_name>
      <phone>00494921981598</phone>
      <email>j.braeunlich@klinikum-emden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <state>North Rhine-Westphalia</state>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Westhoff, Dr.</last_name>
      <phone>004923729082201</phone>
      <email>michael.westhoff@lkhemer.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxonia</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert Wirtz, Prof.</last_name>
      <phone>00493419712600</phone>
      <email>hubert.wirtz@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sana Kliniken Ostholstein</name>
      <address>
        <city>Oldenburg In Holstein</city>
        <state>Schleswig-Holstein</state>
        <zip>23758</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iris Koper, Dr.</last_name>
      <phone>00494361513140</phone>
      <email>iris.koper@sana.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelische Lungenklinik</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Grohé, Prof.</last_name>
      <phone>004930 94802112</phone>
      <email>christian.grohe@jsd.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Hubert Wirtz</investigator_full_name>
    <investigator_title>Head of Pneumology</investigator_title>
  </responsible_party>
  <keyword>nasal high-flow</keyword>
  <keyword>non-invasive ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the recommendations on data sharing by the International Committee of Medical Journal Editors (ICMJE) data resulting from the ELVIS trial will be made available to the scientific community.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>After publication of the major results</ipd_time_frame>
    <ipd_access_criteria>After publication of the major results and upon reasonable request from researchers performing an individual patient data meta-analysis, individual patient data that underlie published results will be shared after de-identification. This requires approval by the local ethics committee of the researcher requesting the data along with public registration of the meta-analysis. The coordinating investigator will contact the data protection officer before de-identification to ensure a correct and actual implementation of this process.&#xD;
Summary statistics that go beyond the scope of published material will be made available to researchers for meta-analysis upon reasonable request and if the necessary data analysis is not unduly time-consuming. Together with publication of the main results, the trial protocol in full will be made publically available as well as the statistical analysis plan.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04881409/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

